Possible Application of Melatonin in Long COVID

Biomolecules, Journal Year: 2022, Volume and Issue: 12(11), P. 1646 - 1646

Published: Nov. 7, 2022

Clinical sequelae and symptoms for a considerable number of COVID-19 patients can linger months beyond the acute stage SARS-CoV-2 infection, “long COVID”. Among long-term consequences cognitive issues (especially memory loss or “brain fog”), chronic fatigue, myalgia, muscular weakness resembling myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) are importance. Melatonin may be particularly effective at reducing signs infection due to its functions as an antioxidant, anti-inflammatory, immuno-modulatory agent. is also chronobiotic medication in treating delirium restoring circadian imbalance seen COVID intensive care unit. Additionally, cytoprotector, melatonin aids prevention several comorbidities, including diabetes, metabolic syndrome, ischemic non-ischemic cardiovascular diseases. This narrative review discusses application neuroprotective agent control deterioration (“brain fog”) pain ME/CFS syndrome-like documented long COVID. Further studies on therapeutic use neurological warranted.

Language: Английский

---

Chronic inflammation, neuroglial dysfunction, and plasmalogen deficiency as a new pathobiological hypothesis addressing the overlap between post-COVID-19 symptoms and myalgic encephalomyelitis/chronic fatigue syndrome

Brain Research Bulletin, Journal Year: 2023, Volume and Issue: 201, P. 110702 - 110702

Published: July 8, 2023

After five waves of COVID-19 outbreaks, it has been recognized that a significant portion the affected individuals developed long-term debilitating symptoms marked by chronic fatigue, cognitive difficulties ("brain fog"), post-exertional malaise, and autonomic dysfunction. The onset, progression, clinical presentation this condition, generically named post-COVID-19 syndrome, overlap significantly with another enigmatic referred to as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Several pathobiological mechanisms have proposed for ME/CFS, including redox imbalance, systemic central nervous system inflammation, mitochondrial Chronic inflammation glial pathological reactivity are common hallmarks several neurodegenerative neuropsychiatric disorders consistently associated reduced peripheral levels plasmalogens, one major phospholipid components cell membranes homeostatic functions. Of great interest, recent evidence revealed reduction plasmalogens contents, biosynthesis, metabolism in ME/CFS acute COVID-19, strong association symptom severity other relevant outcomes. These bioactive lipids increasingly attracted attention due their representing pathophysiological manifestation between aging inflammation. However, alterations plasmalogen or lipidic not yet examined suffering from symptoms. Here, we model based on dysfunctional reactivity, highlighted emerging implications deficiency underlying mechanisms. Along promising outcomes replacement therapy (PRT) various neurodegenerative/neuropsychiatric disorders, sought propose PRT simple, effective, safe strategy potential relief syndrome.

Language: Английский

---

Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia

BMJ Open, Journal Year: 2024, Volume and Issue: 14(5), P. e085272 - e085272

Published: May 1, 2024

Introduction A significant proportion of individuals suffering from post COVID-19 condition (PCC, also known as long COVID) can present with persistent, disabling fatigue similar to myalgic encephalomyelitis/chronic syndrome (ME/CFS) and post-viral syndromes. There remains no clear pharmacological therapy for patients this subtype PCC, which be referred post-COVID (PCFS). low dose the opioid antagonist naltrexone (ie, low-dose (LDN)) has emerged an off-label treatment treating other symptoms in PCC. However, only small, non-controlled studies have assessed LDN so randomised trials are urgently required. Methods analysis prospective, randomised, double-blind, parallel arm, placebo-controlled phase II trial will performed assess efficacy improving PCFS. The decentralised open eligible throughout Canadian province British Columbia (BC). Participants recruited through province-wide Post-COVID-19 Interdisciplinary Clinical Care Network (PC-ICCN) research volunteer platform (REACH BC). Eligible participants 19–69 years old, had a confirmed or physician-suspected SARS-CoV-2 infection at least 3 months prior meet clinical criteria PCFS adapted Institute Medicine ME/CFS criteria. Individuals who taking medications, history liver disease excluded. intervention arm (n=80) placebo (n=80). each prescribed identical capsules starting 1 mg daily follow prespecified schedule up-titration 4.5 maximum tolerated dose. conducted over 16 weeks, assessments baseline, 6, 12 weeks. primary outcome severity weeks evaluated by Fatigue Severity Scale. Secondary outcomes include pain Visual Analogue Scale score, overall symptom measured Patient Phenotyping Questionnaire Short Form, 7-day step count health-related quality life EuroQol 5-Dimension questionnaire. Ethics dissemination been authorised Health Canada approved University Columbia/Children’s Women’s Centre Research Board. On completion, findings disseminated patients, caregivers clinicians engagement activities within existing PCC networks. Results published academic journals presented conferences. Trial registration number NCT05430152 .

Language: Английский

---

Childhood hand, foot and mouth disease sequelae cohort study in Henan, China: cohort profile

BMJ Open, Journal Year: 2025, Volume and Issue: 15(1), P. e083958 - e083958

Published: Jan. 1, 2025

Purpose The childhood hand, foot and mouth disease (HFMD) sequelae cohort study (HNHFMDCS) is an ambispective of patients with HFMD based in Henan Province, China, consisting treated a key hospital for the diagnosis treatment Province. aims to investigate long-term survivors provide comprehensive understanding potential harm caused by this infectious disease. Participants In retrospective phase study, children diagnosed from January 2014 2023 were included, clinical demographic information about was collected through self-developed questionnaire. Patients hospitalised since enrolled prospective follow-up will be performed after completion baseline investigation (interview physical examination), laboratory examination biospecimen collection. Findings date For analysis cohort, total 18 705 cases (11 834 males 6871 females) observed between 2022, which 17 202 mild (10 839 6363 1503 severe (995 508 females). Statistical on data, descriptive statistical methods, including mean value, SD t-test, used compare intergroup data. All tests bilateral, p<0.05 considered statistically significant. There significant differences hospitalisation duration indicators, such as platelets (PLT), C reactive protein (CRP), aspartate amino transferase (AST), alanine (ALT), T lymphocyte subsets (CD3+ CD3+CD4+) B lymphocytes (CD19+) patients. these indicators also help detect changes time so deeply understand social burden disease, strong support rehabilitation Future plans Prospective studies are currently underway, primarily enrolling participate our study. After completed, we conduct cases. coming year, expect obtain preliminary data incidence 1–10 years discharge, well occurrence sequelae. This dataset updated expanded annual basis continuous monitoring patient health progression. From HNHFMDCS, overview common assess make recommendations prevention further disability.

Language: Английский

---

COVID-19 and immune dysfunction: Consequences and natural remedies for management

Elsevier eBooks, Journal Year: 2025, Volume and Issue: unknown, P. 235 - 264

Published: Jan. 1, 2025

Language: Английский

---

Subjective cognitive, psychiatric, and fatigue symptoms two years after COVID-19: a prospective longitudinal cohort study

Brain Behavior & Immunity - Health, Journal Year: 2025, Volume and Issue: unknown, P. 100980 - 100980

Published: March 1, 2025

Language: Английский

---

Kyungok-go for fatigue in patients with long COVID: Double-blind, randomized, multicenter, pilot clinical study protocol

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(4), P. e0319459 - e0319459

Published: April 1, 2025

The most common symptom reported by patients after recovery from coronavirus disease 2019 (COVID-19) is fatigue. However, robust clinical evidence supporting the effectiveness of treatments and interventions for fatigue in COVID-19 survivors lacking. This pilot trial aims to assess safety efficacy Kyungok-go, a herbal preparation targeting fatigue, recovering COVID-19. study will include 100 participants with persistent more than 12 weeks recovery. They be randomly allocated into two groups: Kyungok-go group (n = 50) placebo 50). or administered twice daily weeks, assessed at 4-week intervals. primary outcome change Fatigue Severity Scale score. Secondary outcomes cognitive function, physical quality life, depression, sleep quality, medication adherence, feasibility. first attempt investigate relieving related long COVID. results are expected contribute establishment knowledge base reveal potential medicine prescriptions managing sequelae Trial registration number: KCT0008789 .

Language: Английский

---

Attention deficits and depressive symptoms improve differentially after rehabilitation of post-COVID condition – A prospective cohort study

Journal of Psychosomatic Research, Journal Year: 2023, Volume and Issue: 175, P. 111540 - 111540

Published: Oct. 27, 2023

Language: Английский

---

Adaptogens in Long-Lasting Brain Fatigue: An Insight from Systems Biology and Network Pharmacology

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(2), P. 261 - 261

Published: Feb. 15, 2025

Long-lasting brain fatigue is a consequence of stroke or traumatic injury associated with emotional, psychological, and physical overload, distress in hypertension, atherosclerosis, viral infection, aging-related chronic low-grade inflammatory disorders. The pathogenesis linked to disrupted neurotransmission, the glutamate-glutamine cycle imbalance, glucose metabolism, ATP energy supply, which are multiple molecular targets signaling pathways neuroendocrine-immune blood circulation systems. Regeneration damaged tissue long-lasting multistage process, including spontaneously regulating hypothalamus-pituitary (HPA) axis-controlled anabolic-catabolic homeostasis recover harmonized sympathoadrenal system (SAS)-mediated function, deregulated gene expression rehabilitation. driving mechanism spontaneous recovery regeneration cross-talk mediators neuronal, microglia, immunocompetent, endothelial cells collectively involved neurogenesis angiogenesis, plant adaptogens can target. Adaptogens small molecules origin that increase adaptability organisms stress by interaction HPA axis SAS (neuroendocrine-immune cardiovascular complex), targeting adaptive GPCR pathways. Two major groups comprise (i) phenolic phenethyl phenylpropanoid derivatives (ii) tetracyclic pentacyclic glycosides, whose chemical structure be distinguished as related correspondingly monoamine neurotransmitters (epinephrine, norepinephrine, dopamine) steroid hormones (cortisol, testosterone, estradiol). In this narrative review, we discuss multitarget integrated pharmacological activity botanical ischemic stroke, fatigue; time-dependent dual response physiological regulatory systems support overload; (iii) dose-dependent reversal (hormetic) effect adaptogens. This review shows adaptogenic concept cannot reduced rectified various effects on selected specific modes action without estimating their interactions within networks complex that, turn, regulates other (cardiovascular, gastrointestinal, reproductive systems) due numerous intra- extracellular communications feedback regulations. These result polyvalent pleiotropic adaptogens, essential for characterizing distinct types botanicals. They trigger defense leads extension limits resilience inducing mental For first time, justifies potential particularly hybrid preparation (BHP) Arctic Root Ashwagandha, providing rationale use individuals experiencing fatigue. provided insight into future research network pharmacology preventing rehabilitating following trauma, infections.

Language: Английский

---

The Potential Role of Hypothalamic Phospholipid Liposomes in the Supportive Therapy of Some Manifestations of Post-COVID-19 Condition: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Brain Fog

Journal of Clinical Medicine, Journal Year: 2023, Volume and Issue: 12(17), P. 5478 - 5478

Published: Aug. 23, 2023

Post-COVID-19 condition (commonly known as Long COVID) is a heterogeneous clinical in which Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and brain fog stand out among the different symptoms syndromes. Cerebral metabolic alterations neuroendocrine disorders seem to constitute an important part of pathophysiology (PCC). Given substantial lack specific drugs effective therapeutic strategies, hypothalamic phospholipid liposomes, have been on market for several years adjuvant therapy cerebral resulting from disorders, might represent potential option overall strategy that aims control PCC-associated Their pharmacological mechanisms effects strongly support their effectiveness PCC. Our initial experience seems corroborate this rationale. Further controlled research warranted order verify hypothesis.

Language: Английский

---